These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12357305)

  • 1. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen).
    Boucher E; Corbinais S; Brissot P; Boudjema K; Raoul JL
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):305-8. PubMed ID: 12357305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
    Jang JW; Park YM; Bae SH; Choi JY; Yoon SK; Chang UI; Nam SW; Kim BS
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):415-20. PubMed ID: 15235823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy.
    Ferrari D; Di Maria G; Fazio N; Codecà C; Fiore J; Luciani A; Oldani S; Maggioni M; Foa P
    Anticancer Drugs; 2008 Sep; 19(8):837-40. PubMed ID: 18690097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cantore M; Mambrini A; Fiorentini G; Rabbi C; Zamagni D; Caudana R; Pennucci C; Sanguinetti F; Lombardi M; Nicoli N
    Cancer; 2005 Apr; 103(7):1402-7. PubMed ID: 15726542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
    Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
    Jang JW; Bae SH; Choi JY; Oh HJ; Kim MS; Lee SY; Kim CW; Chang UI; Nam SW; Cha SB; Lee YJ; Chun HJ; Choi BG; Byun JY; Yoon SK
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):9-15. PubMed ID: 16614848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
    Yang TS; Chang HK; Chen JS; Lin YC; Liau CT; Chang WC
    J Gastroenterol; 2004; 39(4):362-9. PubMed ID: 15168248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
    Naganuma A; Toyoda M; Hamada T; Hagiwara S; Yanagisawa M; Kosone T; Arai H; Abe T; Takagi H
    Gan To Kagaku Ryoho; 2007 May; 34(5):729-34. PubMed ID: 17496446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma.
    Saletti P; Berthold D; Ghielmini M; Zucca E; Fazio N; Goldhirsch A; Cavalli F
    Hepatogastroenterology; 2007; 54(75):969-72. PubMed ID: 17591105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma].
    Zhou ZH; Liu LM; Cheng WW; Meng ZQ; Lin JH; Chen Z; Zhang XJ; Jiang GL
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):222-6. PubMed ID: 16875612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
    Lim TY; Cheong JY; Cho SW; Sim SJ; Kim JS; Choi SJ; Choi JW; Kwon HC; Lee KM; Kim JK; Won JH; Yoo BM; Lee KJ; Hahm KB; Kim JH
    Korean J Hepatol; 2006 Mar; 12(1):65-73. PubMed ID: 16565607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.
    Ikeda M; Okusaka T; Ueno H; Morizane C; Kojima Y; Iwasa S; Hagihara A
    Jpn J Clin Oncol; 2008 Oct; 38(10):675-82. PubMed ID: 18716041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
    Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
    Lin CC; Hsu CH; Huang CY; Cheng AL; Chen J; Vogelzang NJ; Pu YS
    Cancer; 2006 Mar; 106(6):1269-75. PubMed ID: 16470604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
    Ikeda M; Okusaka T; Ueno H; Takezako Y; Morizane C
    Cancer; 2005 Feb; 103(4):756-62. PubMed ID: 15637692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein.
    Itamoto T; Nakahara H; Tashiro H; Haruta N; Asahara T; Naito A; Ito K
    J Surg Oncol; 2002 Jul; 80(3):143-8. PubMed ID: 12115797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
    J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma.
    Al-Amro A; Al-Rajhi N; Khafaga Y; Memon M; Al-Hebshi A; El-Enbabi A; El-Husseiny G; Radawi A; Belal A; Allam A; El-Sebaie M
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):508-13. PubMed ID: 15890594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.